Revenue Growth - Total revenue for the three months ended June 30, 2024, increased to $622,000, a 203.4% increase compared to $205,000 for the same period in 2023[107] - Product revenue for the three months ended June 30, 2024, was $584,000, representing a 212.3% increase from $187,000 in the same period in 2023[107] - Total revenue for the six months ended June 30, 2024, was $1,079,000, a 135.1% increase from $459,000 in the same period in 2023[107] Profitability - Gross profit for the three months ended June 30, 2024, was $354,000, a 353.8% increase compared to $78,000 for the same period in 2023[111] - Gross profit for the six months ended June 30, 2024, was $623,000, a 208.4% increase compared to $202,000 for the same period in 2023[111] - The company reported a net loss of $23,099,000 for the three months ended June 30, 2024, a decrease from a net loss of $25,573,000 in the same period in 2023[107] Expenses - Research and development expenses decreased by $1.5 million, or 9.2%, for the three months ended June 30, 2024, compared to the same period in 2023[113] - Research and development expenses for the six months ended June 30, 2024, decreased by $7.5 million, or 22.1%, compared to the same period in 2023[113] - Selling, general and administrative expenses increased by $1.3 million, or 11.6%, for the three months ended June 30, 2024, compared to the same period in 2023, primarily due to a $0.9 million increase in stock-based compensation[115] Cash Flow - Net cash used in operating activities was $41.8 million for the six months ended June 30, 2024, a decrease of $9.8 million compared to $51.6 million for the same period in 2023[125] - Net cash used in investing activities was $32.6 million for the six months ended June 30, 2024, compared to net cash provided of $55.2 million for the same period in 2023[126] - As of June 30, 2024, the company had cash and cash equivalents and investments in marketable securities totaling $218.1 million[129] Future Outlook - The company expects to incur negative operating cash flows on an annual basis for the foreseeable future until it can scale revenue growth[128] - The company initiated a full commercial launch of the Platinum instrument at the end of the first quarter of 2024, following a controlled launch in December 2022[105] - The company believes its platform could be utilized for various applications, including biomarker discovery and vaccine development[105] Market and Economic Factors - Inflation has impacted the underlying cost of supplies and manufacturing components, potentially harming the company's financial condition if costs cannot be offset[138] - As of June 30, 2024, the company's marketable securities primarily consist of investments in money market funds, U.S. Treasury bills, and high-quality corporate commercial paper, focusing on capital preservation[139] - The company currently operates mainly in the U.S. and anticipates future expansion into Europe and other regions, which may involve transactions in currencies other than the U.S. Dollar[140] - Foreign currency translation risk is not expected to have a material impact on the company's financial statements in the near term, but this may change as international operations grow[140] - The company has not entered into any hedging arrangements for foreign currency risk to date, but will reassess its approach as operations expand[140] Investment and Income - Dividend and interest income increased by $0.4 million, or 16.3%, for the three months ended June 30, 2024, and by $1.8 million, or 37.4%, for the six months ended June 30, 2024, compared to the same periods in 2023[118] - There was no gain or loss on marketable securities for the three and six months ended June 30, 2024, compared to a loss of $1.2 million and a gain of $1.8 million for the same periods in 2023[120] - The change in fair value of warrant liabilities decreased by $0.5 million for the three months ended June 30, 2024, compared to an increase of $0.3 million for the same period in 2023[121] - Other (expense) income, net, decreased by $0.3 million, or 103.7%, for the three months ended June 30, 2024, compared to the same period in 2023[122]

Revenue and Profit - Reported revenue of $622,000 in the second quarter of 2024[2] - Gross profit of $354,000 with a gross margin of 57% in Q2 2024[3] - Total revenue for Q2 2024 increased to $622K, up 203% from $205K in Q2 2023[14] - Gross profit for Q2 2024 rose to $354K, a 354% increase from $78K in Q2 2023[14] Operating Expenses - Total operating expenses of $26.8 million in Q2 2024, compared to $27.0 million in the prior year[3] - Adjusted total operating expenses of $24.4 million in Q2 2024, compared to $24.0 million in the prior year[3] - Research and development expenses for Q2 2024 decreased to $14,381K from $15,834K in Q2 2023[14] - Selling, general and administrative expenses for Q2 2024 increased to $12,424K from $11,136K in Q2 2023[14] - Adjusted total operating expenses for Q2 2024 were $24,374K, compared to $24,038K in Q2 2023[16] Net Loss and Adjusted EBITDA - Net loss of $23.1 million in Q2 2024, compared to a net loss of $25.6 million in the prior year[3] - Adjusted EBITDA of negative $22.6 million in Q2 2024, compared to negative $22.9 million in the prior year[3] - Net loss for Q2 2024 improved to $(23,099)K, compared to $(25,573)K in Q2 2023[14] - Adjusted EBITDA for Q2 2024 was $(22,633)K, slightly better than $(22,870)K in Q2 2023[15] Cash and Investments - Cash and cash equivalents and investments in marketable securities totaled $218.1 million as of June 30, 2024[4] - Dividend and interest income for Q2 2024 was $2,887K, up from $2,483K in Q2 2023[14] Product Launches and Development - Expects to launch a version 2 library prep kit and a barcoding application specific library prep kit by the end of 2024[2] - Announced the launch of the version 3 sequencing kit[2] - Completed the first quarter of full commercial launch of the Platinum instrument in Q2 2024[2] Other Financial Metrics - Stock-based compensation for Q2 2024 was $2,400K, compared to $1,865K in Q2 2023[15] - Restructuring costs for Q2 2024 were $31K, down from $1,067K in Q2 2023[15]

Quantum-Si Incorporated (NASDAQ:QSI) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Katherine Atkinson - Senior Vice President-Commercial Marketing Jeff Hawkins - President and Chief Executive Officer Jeff Keyes - Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - HCW Kyle Mikson - Canaccord Genuity Operator Ladies and gentlemen, thank you for standing by. Welcome to the Quantum-Si First Quarter 2024 Earnings Call. At this time, all participants are i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: For the transition period from ________ to ___ ...

Exhibit 99.1 Quantum-Si Reports First Quarter 2024 Financial Results Executed Full Commercial Launch of Platinum® Instrument Reaf irms Full Year 2024 Financial Guidance BRANFORD, Conn. -- (BUSINESS WIRE) – May 9, 2024 -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced financial results for the first quarter ended March 31, 2024. Press Release Highlights "We concluded our first quarter of 2024 with great momentum on all fronts, i ...

Quantum-Si Incorporated (NASDAQ:QSI) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET Company Participants Katherine Atkinson – Senior Vice President-Commercial Marketing Jeff Hawkins – President and Chief Executive Officer Jeff Keyes – Chief Financial Officer Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Quantum-Si Fourth Quarter and Full Year 2023 Earnings Call. At this time, all partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 85-1388175 (State or other jurisdiction of incorp ...

Exhibit 99.1 Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results Finalizing Commercial Readiness for Expected Full Commercial Launch by the End of Q1 2024 Releases Full Year 2024 Financial Guidance BRANFORD, Conn. -- (BUSINESS WIRE) – Feb. 29, 2024 -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023. Press Release Highlights "We made ...

Quantum-Si Incorporated (NASDAQ:QSI) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Katherine Atkinson - SVP, Commercial Marketing Jeff Hawkins - President and Chief Executive Officer Jeff Keyes - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Swayampakula Ramakanth - H.C. Wainwright Operator Good day and thank you for standing by. Welcome to the Quantum-Si Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 85-1388175 ...